Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Geron Corp (NQ: GERN )

4.370 -0.140 (-3.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Geron Corp

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
7 Must-Own Small-Cap Stocks That Could Outperform the Market
If you’re ready to absorb significant risk for the chance of ridiculous upside, these small-cap stocks to buy may be just for you. 
Via InvestorPlace
Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS
From Geron Corporation
Via Business Wire
Recent Pullback Buying Opportunity For Blood Cancer Firm Geron: Goldman Sachs
Goldman Sachs has upgraded Geron Corporation (NASDAQ: GERN) to Buy from Neutral, with a p 
Via Benzinga
Why Is Geron (GERN) Stock Up Today?
Geron (GERN) stock is gaining on Tuesday following an upgrade for the biopharmaceutical company's shares from Goldman Sachs. 
Via InvestorPlace
Geron (GERN) Q2 2023 Earnings Call Transcript
GERN earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023
Via Benzinga
Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer
From Geron Corporation
Via Business Wire
Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting
From Geron Corporation
Via Business Wire
Geron to Participate in the Baird 2023 Global Healthcare Conference
From Geron Corporation
Via Business Wire
Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS
From Geron Corporation
Via Business Wire
Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS
From Geron Corporation
Via Business Wire
Why Macy's Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shares jumped 42.8% to $5.60 after the FDA lifted clinical hold on the company’s FTX-6058 for sickle cell disease. 
Via Benzinga
Exposures Product Safety
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results
From Geron Corporation
Via Business Wire
Geron to Announce Second Quarter 2023 Financial Results on August 3, 2023
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Thoughts For Thursday: Back From The Holiday With Caution
Caution is perhaps what was reflected in yesterday's back from the holiday trading. One there is the question of upcoming Fed action and second there is the visit of Secretary Yellen to China. 
Via Talk Markets
Geron Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS
From Geron Corporation
Via Business Wire
Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now
With longevity back in the news, many investors are wondering which biotech stocks to buy to best cash in on the growing trend. 
Via InvestorPlace
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
What's Going On With Geron Stock Today
Geron Corporation (NASDAQ: GERN) submitted a marketing application with the FDA seeking approval for imetelstat for the treatment of transfusion-dependent anemia in adult patients with low- to... 
Via Benzinga
Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat
From Geron Corporation
Via Business Wire
Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS
From Geron Corporation
Via Business Wire
Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients
From Geron Corporation
Via Business Wire
Geron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
From Geron Corporation
Via Business Wire
Geron to Host Virtual Investor Event on June 14, 2023
From Geron Corporation
Via Business Wire
Market Mixes It Up With A Broad Rally
Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive. 
Via Talk Markets
Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence with Imetelstat in IMerge Phase 3 Lower Risk MDS Patients
From Geron Corporation
Via Business Wire
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Onfolio Holdings, Inc. (NASDAQ: ONFO) gained 73% to $2.02 after the company announced it completed development of a generative AI search tool. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.